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Abstract 
 
Novel antimalarial therapies are needed in the face of emerging resistance to 
artemisinin combination therapies. A previous study found a high cure rate in 
Mozambican children with uncomplicated Plasmodium falciparum malaria 7 days post 
treatment with a fosmidomycin-clindamycin combination. However, 28-day cure rates 
were low (45.9%), due to parasite recrudescence. We sought to identify any genetic 
changes underlying parasite recrudescence. To this end, we utilized a selective whole 
genome amplification method to amplify parasite genomes from blood spot DNA 
samples. Parasite genomes from pre-treatment and post-recrudescence samples were 
subjected to whole genome sequencing to identify nucleotide variants. We find that our 
data do not support the existence of a genetic change responsible for recrudescence 
following fosmidomycin-clindamycin treatment. Additionally, we find that previously 
described resistance alleles for these drugs do not represent biomarkers of 
recrudescence. Future studies should continue to optimize fosmidomycin combinations 
for use as antimalarial therapies. 
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Background 
Malaria remains a serious global health concern, with ~214 million cases and 483,000 
deaths due to malaria in 2015 [1]. A majority of severe malaria cases occur in pregnant 
women and children under five years of age and result from infection with the parasite 
Plasmodium falciparum [1]. Artemisinin combination therapies (ACTs) represent the 
current first-line treatment in endemic areas. Historically, the development of drug 
resistance has hindered malaria control. As delayed parasite clearance has emerged for 
ACTs in Southeast Asia and has continued to spread [1,2], new antimalarials are 
urgently needed. 
 
One such potential therapeutic is the phosphonic acid antibiotic fosmidomycin (FSM). 
FSM is a well-characterized inhibitor of the first committed step of isoprenoid precursor 
synthesis via the methylerythritol phosphate (MEP) pathway [3–5]. Because humans 
synthesize isoprenoids via an enzymatically distinct metabolic route (mevalonate 
pathway), FSM is a highly specific inhibitor of malaria parasite growth [3,5] and is well-
tolerated in humans [6,7].  
 
FSM was originally developed as an antibacterial [8] and is currently under evaluation 
as a partner agent for combination therapy against uncomplicated P. falciparum malaria 
(clinicaltrials.gov identifier NCT02198807). Several studies have paired FSM with the 
antibiotic clindamycin (CLN), a protein translation inhibitor (clinical trials NCT02198807, 
NCT01361269, NCT01002183, NCT00214643, and NCT00217451) [6,9,10]. One such 
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Phase II clinical trial, performed in Mozambique in 2010, evaluated the efficacy of a 
FSM-CLN combination on uncomplicated malaria in children aged 6-35 months, the 
youngest cohort tested to date [11,12]. A high parasite cure rate was observed at day 7 
post-treatment with FSM-CLN (94.6%). Unfortunately, the cure was not durable, and the 
post-treatment PCR-corrected day 28 cure rate was 45.9% (17/39), due to recrudescent 
infections. Parasite recrudescence is common in clinical studies of FSM efficacy, with 
an overall day 28 cure rate of ~70% in adults [12].  
 
The safety and specificity of MEP pathway-targeting therapeutics, such as FSM, are 
highly desirable. However, the failure of FSM treatment to result in lasting cure has led 
to concern regarding the clinical utility of FSM or related antimalarials. We recently 
found that FSM resistance is readily achieved in culture due to mutations in the 
metabolic regulator PfHAD1 (PlasmoDB ID PF3D7_1033400) [13]. Additionally, CLN 
resistance has been reported in clinical isolates of P. falciparum, attributed to mutation 
in the apicoplast 23S rRNA [14].  
 
In this study, we address whether observed recrudescence is produced by selection for 
mutations in previously identified candidate genes or novel resistance loci.. Using 
selective whole genome amplification (SWGA) and sequencing, we characterize P. 
falciparum field isolates from blood spot samples to evaluate the genetic landscape of 
drug resistance before and after FSM-CLN treatment. Specifically, we evaluate for 
enrichment in genetic changes associated with decreased susceptibility to either FSM 
or CLN.  
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Methods 
 
Study information 
The study criteria have been previously described [11]. The study evaluated 37 children 
ages 6-35 months with uncomplicated malaria. Inclusion and exclusion criteria are 
outlined in the original study [11]. Patients were administered a three-day, twice-daily 
course of oral FSM-CLN. Blood spots were collected at days 0, 7, 14, and 28, and if 
applicable, upon recrudescence. 
 
Clinical trial information 
The original trial in Mozambique, sponsored by Jomaa Pharma, was conducted in 2010 
according to the ICH Good Clinical Practice guidelines. The protocol was approved by 
the National Mozambican Ethics Review Committee and the Hospital Clinic of 
Barcelona Ethics Review Committee. The clinicaltrials.gov identifier is NCT01464138. 
 
Selective whole genome amplification 
Blood spotting and DNA isolation has been previously described [11]. SWGA of P. 
falciparum genomes was performed as described previously [15], including primer sets 
(Supplementary Table 2) and reaction conditions. Reactions contained 10 ng template 
and 3.5 μM primer set 6A. Reactions were cleaned using Ampure beads (Beckmann 
Coulter) at a 1:1 DNA:bead ratio. Samples underwent a second round of SWGA using 
primer set 8A and 15-30 ng DNA. 
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PCR of SWGA products 
Selective amplification of P. falciparum genomes was verified by PCR using P. 
falciparum- or human-specific primers (Supplementary Table 1). Human DNA and 
human-specific primers were kindly provided by Shiming Chen (Washington University). 
Reactions contained 2 μM each primer, 25-50 ng bead-cleaned SWGA product, and 
BIO-X-ACT Short PCR Mix (Bioline). Vendor-recommended cycling conditions were 
used, with modifications: (55 °C and 60 °C annealing for P. falciparum- and human-
specific primers, respectively; 68 °C extension). Amplicons were visualized by agarose 
gel electrophoresis. 
 
Whole genome sequencing 
Library preparation, Illumina sequencing, read alignments, and variant calling were 
performed by the Washington University Genome Technology Access Center (GTAC).  
Bead-cleaned SWGA product DNA (0.5-1.2 μg) was sheared, end-repaired, and 
adapter-ligated. PCR-based libraries were sequenced on an Illumina HiSeq 2500 to 
generate 101 bp paired end reads. Reads were aligned to the 3D7 reference 
(PlasmoDB v24) using Novoalign (V2.08.02) [16]. Duplicate reads were removed. SNPs 
were called using samtools (mpileup) [17], filtered (quality ≥20, read depth ≥5), and 
annotated using snpEff (3.3c, build 2013-06-28) [18]. 
 
P. falciparum reads are available through the NCBI BioProject database 
(PRJNA315887) and Sequence Read Archive (SRP072442).  
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For some analyses (comparison of SNPs in resistance genes, GO analysis), only 
sample pairs with both exomes showing sufficient coverage (≥60% covered at ≥5X, 
indicated in Supplementary Table 3) were used. Given a per-base error rate of 0.1-0.5% 
for Illumina sequencing [19,20], 5X coverage equates to >99.9% accuracy. Studies 
have indicated reasonable sensitivity and accuracy for our variant caller at this cutoff 
[21]. 
 
SNPhylo plot generation 
Multi-sample VCFs were converted to hapmap format. SNPhylo [22] was run with the 
default settings, with an LD cutoff of 0.8. 
 
Multiplicity of infection (MOI) determination 
MOI was determined using the WHO-recommended PCR-based genotyping procedures 
at the MSP1 (PF3D7_0930300), MSP2 (PF3D7_0206800), and GLURP 
(PF3D7_1035300) loci [23]. 
 
Sequencing of the apicoplast 23S rRNA locus 
The apicoplast 23S rRNA (PlasmoDB ID PCF10_API0010:rRNA) locus was amplified 
by PCR. Reactions contained 2 μM of each primer 23S_1 and 23S_6 (Supplementary 
Table 1), 4-5 μL of blood spot DNA, and CloneAmp HiFi PCR Premix (Clontech). 
Vendor-recommended cycling conditions were used (55 °C primer annealing). 
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Amplicons were Sanger sequenced using primers 23S_1 – 23S_6 (Supplementary 
Table 1). 
 
GO analysis 
GO term enrichment of genes containing SNPs unique to post-treatment samples was 
determined using the PlasmoDB Gene Ontology Enrichment tool [24] (Bonferroni-
corrected p-value <0.01). 
 
Results 
 
Selective whole genome amplification of blood spot DNA generates parasite 
templates for whole genome sequencing 
We evaluated blood spot DNA (mixed human and P. falciparum) from 12 patient 
samples with microscopic recrudescent infection (12 pre- and post-treatment pairs, 24 
samples total). Pilot unmodified, low-input library preparation methods resulted in <5% 
reads mapping to the P. falciparum genome. For this reason, we used SWGA to amplify 
P. falciparum DNA. This method uses the processive Φ29 DNA polymerase and 
genome-specific primers to selectively amplify a target genome from a mixed sample 
[25–27] and has been recently used to characterize chimpanzee Plasmodium genomes 
[15]. 
 
Enrichment of the P. falciparum genome was verified by PCR (Figure 1). We amplified 
P. falciparum genomes from a broad range of parasite densities (18-315,064 
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parasites/μL whole blood). Amplified samples were used to prepare libraries for Illumina 
sequencing. 
 
The samples displayed varying degrees of sequencing success (Supplementary Table 
3). An average (± S.E.M.) of 55.1% ± 2.9% of reads mapped to the P. falciparum 
genome, resulting in 48.1% ± 3.5% of the genome covered at ≥5X. This is comparable 
to previous studies using SWGA to sequence microbial genomes [27,28]. The genome 
coverage we obtain is consistent with very low proportions (<0.01%) of parasite DNA in 
the blood spot samples [15]. While more reads will increase genome coverage, 
including typically low-coverage intragenic regions, coverage is likely to be limited by 
incomplete genome representation in the sample, as very low proportions of parasite 
DNA are likely to result in incomplete or inefficient SWGA of some genome regions. 
Given the low coverage of AT-rich intragenic regions, our analyses focused on protein-
coding regions of the P. falciparum genome. We observe an average of 69.0% ± 4.4% 
of the exome covered ≥5X, with as much as 90% of the exome covered ≥5X 
(Supplementary Table 3).  
 
We observe an average of 35,451 ± 1,220 total genome SNPs in our sequenced 
samples, consistent with recent studies of African field isolates [29,30]. Of these, 15,862 
± 534 are exome SNPs. We find an average of 10,755 ± 349 non-synonymous SNPs in 
our samples with sufficient exome coverage (≥60% covered at ≥5X). 
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SNP profiling confirms recrudescent infections 
Maximum-likelihood phylogenetic tree construction from our exome SNP profiles from 
the 12 pre- and post-treatment sample pairs demonstrates clustering by patient-of-origin 
(Figure 2). These data support the conclusion that all infections analyzed indeed reflect 
failure to completely clear the original infection (recrudescence), as opposed to novel, 
independent infections. Pre-treatment and post-treatment samples share a majority 
(66.0 ± 3.4%) of non-synonymous SNPs, while independent (between-patient) pre-
treatment infections are less related and share only 24.6 ± 0.4% of non-synonymous 
SNPs (strains with ≥60% of the exome at ≥5X, N=8). These data confirm the genotyping 
reported in the original study [11], which established recrudescence through WHO-
recommended PCR-based genotyping at three P. falciparum loci: MSP1, MSP2, and 
GLURP [23].  
 
Multiplicity-of-infection (MOI) pre- and post-treatment  
In high transmission areas, patients may be simultaneously infected with multiple 
parasite strains. This genetic variation provides a potential reservoir for the 
development of resistance to antimalarials, both within a given patient and in the larger 
P. falciparum population. Multiplicity-of-infection (MOI) has been shown to decrease 
after recrudescence following chloroquine treatment [31], and, unsurprisingly, increased 
MOI is correlated with treatment failure [32]. However, during any individual infection, 
selective pressures during infection (such as immune evasion) and drug treatment are 
expected to decrease genetic diversity. We therefore assessed MOI before and after 
recrudescence. 
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All infections were polyclonal, with a mean pre-treatment MOI of 3.9 ± 0.3. This is 
slightly higher than MOIs reported in other pediatric studies in Mozambique [33,34]. MOI 
decreased modestly in two-thirds of the samples after treatment and recrudescence, 
with a mean post-treatment MOI of 3.2 ± 0.2 (p=0.0065, paired t-test). This reduction 
was not a result of lower parasitemias in recrudescent infections, as average post-
treatment parasite density was approximately equal to average pre-treatment parasite 
density (76,225 ± 33,944 vs. 70,977± 20,498 parasites/μL). Additionally, MOI and 
parasite density were not correlated (Pearson r = -0.041, p = 0.849). 
 
Of note, loss-of-function mutations in the FSM-resistance gene PfHAD1 have been 
infrequently reported in the genomes of field P. falciparum isolates (PlasmoDB, 
accessed April 2016), suggesting that such alleles are rare [24]. Therefore, if resistance 
emerges during the course of infection in a given patient, recrudescence due to 
outgrowth of a rare resistant clone should result in a dramatic decrease in MOI. This 
was not observed in our population, suggesting that FSM resistance alone is unlikely to 
account for recrudescence of patients treated with FSM-CLN.  
 
Genotyping of known resistance loci does not reveal a change in the resistance 
landscape between pre- and post-treatment samples 
To evaluate whether FSM-CLN recrudescent parasites have genetic changes 
associated with drug resistance, we investigated the genomes of paired pre- and post-
treatment parasites for genetic markers of antimalarial resistance. We evaluated loci 
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previously implicated in resistance to FSM or CLN, as well as loci documented to 
contribute to resistance to other clinically available antimalarials. 
 
FSM targets the isoprenoid synthesis enzyme 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase (PfDXR, PF3D7_1467300). Following FSM-CLN treatment, 
recrudescent samples are not enriched in alternative PfDXR alleles (Figure 3, 
Supplementary Table 4). One sample (114) possesses the Q361R PfDXR allele, 
previously reported in African isolates [24]. The homologous residue (R276) in FSM-
sensitive Escherichia coli DXR (NCBI reference NP_414715.1) is identical to the 
mutated residue (361R). Therefore, the DXR Q361R variant is unlikely to confer FSM 
resistance. 
 
We have recently identified a metabolic regulator, PfHAD1, whose loss results in FSM 
resistance in cultured P. falciparum [13]. No PfHAD1 loss-of-function alleles were 
identified in our samples (Figure 3, Supplementary Table 4), consistent with a known 
lack of variation in this gene in field samples [24]. The N70S allele seen in a number of 
strains has been previously reported as a common wild-type variant [24], which does 
not confer FSM resistance [13]. Two pre-treatment samples (103 and 118) possessed 
additional polymorphisms in PfHAD1, S265L and E150K, respectively (Figure 3, 
Supplementary Table 4). These alleles are not predicted to affect PfHAD1 function 
[Polyphen-2 scores < 0.005 (benign)] [35] and are not enriched in the recrudescent 
samples. Altogether, our data indicate that known markers of FSM resistance in PfDXR 
and PfHAD1 do not emerge during the course of FSM treatment. Thus, known 
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mechanisms of FSM resistance observed in the laboratory are unlikely to represent the 
underlying mechanism behind FSM-CLN failure. Since recrudescent parasites were not 
culture-adapted, we cannot distinguish whether these parasites were resistant or just 
failed to be cleared. Therefore, it is possible that resistance-causing mutations in 
PfDXR, PfHAD1, or other loci might occur if parasites were subjected to longer drug 
exposures.  
 
Resistance to the FSM partner agent, CLN, has also been reported in P. falciparum 
[14]. In this previous study, mutation (A1875C) in the 23S rRNA locus 
(PFC10_API0010) is associated with an approximately 100-fold increase in clindamycin 
IC50 for clinical isolates [14]. Insufficient coverage of the plastid genome was obtained 
from whole genome sequencing; we therefore used targeted gene amplification and 
sequencing to interrogate for polymorphisms in PFC10_API10010. No samples 
possessed the A1875C variant. All sequenced samples matched the FSM- and CLN-
sensitive 3D7 control strain (Supplementary Data 1). Notably, from our sequencing of 
laboratory 3D7 and HB3 strains, we identify variations not reported in the genome 
reference (T451A, A454T, and 401insG) (Supplementary Data 1) [24]. These changes 
may have emerged over time during culturing of laboratory isolates. 
 
Finally, we interrogated the prevalence of other drug resistance markers before and 
after FSM-CLN treatment (Figure 3, Supplementary Table 4). Specifically, we evaluated 
variation in the locus encoding the multi-drug transporter PfMDR1 (PF3D7_0523000), 
which modulates parasite sensitivity to hydrophobic antimalarials, such as mefloquine 
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and halofantrine [36]. Strains possessing PfMDR1 mutations are sensitive to FSM and 
PfMDR1 mutations are not predicted to impact FSM effectiveness [3,37]. Three 
PfMDR1 variants (wild-type, Y184F, and N86Y) were identified in our analyzed strains, 
but PfMDR1 haplotype frequencies were not significantly different in pre- and post-
treatment populations (p>0.5).  
 
ACTs, introduced in Mozambique in 2004 [38], may have selected for parasites able to 
withstand drug treatment such as FSM-CLN. Alleles of PfK13 (Kelch13, 
PF3D7_1343700) have been implicated in artemisinin resistance. We identify two PfK13 
variants in our population (K189T and A578S), neither of which has been implicated in 
laboratory artemisinin resistance. The K189T variant is common in African isolates 
[39,40] and is not believed to cause increased clearance times following ACT. While the 
A578S variant has been associated with increased clearance times [41], this mutation 
was only observed in a small fraction of our strains. Additionally, strains possessing 
known resistance mutations in PfK13 are FSM sensitive (Edwards RL et al., submitted) 
suggesting that selection for artemisinin resistance does not result in FSM resistance. 
 
In our small study population, selection with FSM-CLN did not appear to alter frequency 
of PfMDR1 alleles or alleles of additional known genetic loci associated with antimalarial 
resistance, including PfCRT (chloroquine), PfATP4 (multiple drug classes), PfDHFR 
(antifolates), and PfDHPS (antifolates) (Figure 3, Supplementary Table 4) [42–46].  
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Our approach permitted an unbiased search for any novel non-synonymous SNPs that 
are associated with recrudescence following FSM-CLN treatment. To better understand 
SNPs that were unique to or enriched in recrudescent samples, we also subtracted pre-
treatment non-synonymous SNPs from post-treatment non-synonymous SNPs. The 
eight recrudescent strains analyzed had an average of 3,448 ± 604 unique non-
synonymous SNPs (approximately 33% of their total non-synonymous SNPs).  
 
Sixty-eight SNPs were shared in ≥50% of the samples (Supplementary Table 5). 
However, no non-synonymous SNPs were shared between all 8 recrudescent samples, 
demonstrating that, in this small population, a genetic marker of recrudescence was not 
present. 
 
Selective pressures in vivo are likely to be distinct from those described in vitro. We 
hypothesized that certain biological processes may be enriched for genetic variation in 
our post-treatment samples. We therefore performed gene ontology (GO) analysis on 
the genes with SNPs shared in ≥50% of recrudescent samples (Supplementary Table 5) 
to understand the functions of genes containing SNPs enriched upon recrudescence. 
Our analysis reveals enrichment for immune evasion and parasitism-related functions 
(Table 1). This result has been observed in other studies of variation in P. falciparum 
populations [14,30]. Because these genes are among the most variable in a population, 
they are likely to display changes in allele frequency following a population bottleneck, 
such as recrudescence. Notably, GO analysis did not reveal enrichment in pathways 
associated with drug resistance or with the mechanism of action of FSM (isoprenoid 
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synthesis) or CLN (protein translation). While a novel genetic route to FSM or CLN 
resistance is possible, we see no evidence for enrichment of new SNPs or pathways in 
our unbiased genome analysis. 
 
Discussion 
Fosmidomycin (FSM) is an antimalarial with a novel, parasite-specific mechanism-of-
action, a well-characterized target, and exceptional clinical safety. Despite this promise, 
FSM combination treatment of uncomplicated P. falciparum infection in children was 
unsuccessful due to unacceptably high rates of parasite recrudescence [11]. Parasite 
FSM resistance arises readily in culture and has been attributed to loss-of-function 
mutations in PfHAD1 [13]. These in vitro studies suggested that selection for FSM 
resistance alleles during clinical infection and/or FSM treatment may represent a 
mechanism to explain clinical failures following FSM treatment.  
 
To address this concern, we have surveyed the genetic diversity in Mozambican 
pediatric P. falciparum malaria infections before and after treatment failure with FSM-
CLN. Overall, our data indicate that drug resistance does not account for treatment 
failures following FSM-CLN therapy. Our results confirm that treatment and 
recrudescence represent a population bottleneck, as MOI is decreased in recrudescent 
samples. Since resistance alleles are thought to represent only a miniscule proportion of 
the pre-treatment population, the modest decrease in MOI that we observe is 
inconsistent with the selection of resistant strains from the population.  
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Importantly, we do not find evidence of SNPs enriched in parasites following FSM-CLN 
treatment. Specifically, we do not identify enrichment for alleles already experimentally 
implicated in FSM or CLN resistance. Our use of whole genome sequencing permits an 
unbiased screen for additional SNPs that may contribute to resistance, regardless of 
whether these alleles are directly responsible or otherwise associated with a 
recrudescent phenotype. While we are limited by the retrospective nature of our study 
and our inability to phenotype culture-adapted recrudescent parasites, both FSM and 
CLN have single, well-characterized targets and known SNPs underlying resistance 
[13,14]. We therefore conclude that neither FSM nor CLN resistance is responsible for 
clinical failure of FSM-CLN.  
 
Our study was designed to evaluate the hypothesis that a simple coding mutation may 
underlie recrudescence in FSM-CLN-treated parasites. The results of our study cannot 
exclude other potential routes to resistance, such as non-coding mutations resulting in 
regulatory variation or non-genetic changes in gene expression or homeostatic 
responses. Further studies may address if and how these mechanisms contribute to 
resistance to FSM, CLN, and other antimalarials. 
 
Our study highlights an important caution in applying the results of forward genetic 
screening in cultured parasites to clinical populations. As resistance alleles are 
identified in vitro, it is important to recognize that selective pressures during natural 
human infection (immune pressure, metabolic requirements) are likely to be distinct. 
Our data indicate that mutation in PfHAD1 is not readily achieved in clinical populations. 
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Perhaps mutation of PfHAD1 comes at a fitness cost in P. falciparum, similar to what 
has been found for other resistance loci, such as PfCRT and PfATP4 [47,48]. However, 
PfHAD1 mutation appears to reduce fitness during human infection and not during 
culture, as loss of PfHAD1 is easily achieved in laboratory selections. 
 
Finally, our study illustrates the utility of SWGA for the analysis of P. falciparum 
genomes from blood spot samples. This method has applications for future field studies, 
as blood spots are easier to acquire than whole blood. Further optimization will facilitate 
the extraction of more data from these types of samples. Furthermore, our data provide 
additional validation of PCR-based strategies to determine MOI and recrudescence. We 
find that the high rate of recrudescence following FSM-CLN treatment in children was 
not overestimated due to use of the standard 3-locus PCR genotyping protocol [11]. 
Eventual use of whole genome sequencing for genotyping field populations will provide 
more information regarding variation within a geographic region and within patients. 
 
This work supports the current hypothesis that the disappointing clinical efficacy of FSM 
combinations is likely due to challenges of partner drug selection and formulation [12]. 
The short serum half-life of both FSM and CLN (1-3 h) limits parasite exposure and 
presumably reduces the selective pressure for resistance [8,49]. However, this limited 
serum exposure almost certainly contributes to decreased clinical efficacy. Currently, 
FSM is being evaluated in combination with the bisquinolone piperaquine in a Phase II 
clinical trial in Gabon (NCT02198807). Piperaquine has a notably long half-life (>20 
days) [50], which holds promise to limit recrudescence when paired with FSM. Our 
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findings support the continued development of antimalarials targeting PfDXR and the 
MEP pathway, as well as the development of alternative FSM combinations. 
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Figure Legends 
 
Figure 1. SWGA causes enrichment of P. falciparum DNA from mixed samples 
that can be detected by PCR. Shown is an agarose gel of SWGA amplicons 
obtained using P. falciparum-specific (top) and human-specific (bottom) primers. 
Markers indicate DNA size in base pairs.  
 
Figure 2. Samples cluster by patient, indicating recrudescent infections. SNPhylo 
[22] was used to construct a maximum likelihood phylogenetic tree of SNP 
profiles from initial (pre-treatment) and recrudescent (post-treatment) infections. 
Bootstrap values were 100 for all pre- and post-treatment branch points. Samples 
are numbered by infection. Scale bar represents units of substitution. 
 
Figure 3. Resistance landscape before and after recrudescence. Only infection 
pairs with sufficient exome coverage were analyzed (≥60% at ≥5X, N=8). Shown 
are the percentages of pre- and post-treatment samples with indicated non-
reference (3D7) alleles at resistance loci. Any codons not shown match the 3D7 
reference in all samples. 
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Table 1. Gene ontology (GO) analysis of genes containing SNPs unique to 
recrudescent samples.  
GO term ID Description p-value 
GO:0051704 multi-organism process 1.5 x 10-4 
GO:0044403 
symbiosis, encompassing mutualism through 
parasitism 
1 x 10-3 
GO:0044419 interspecies interaction between organisms 1 x 10-3 
GO:0016337 cell-cell adhesion 3.6 x 10-3 
GO:0009405 pathogenesis 4.6 x 10-3 
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